IRF2 and hepatocellular carcinoma: IRF2/β-catenin pathway was stimulated in HCC LR cells, and inhibiting β-catenin with the use of XAV-939 effectively significantly enhanced the efficacy of lenvatinib by promoting cell apoptosis 31.